Bayer HealthCare will seek FDA approval for its new colorectal cancer drug, regorafenib, and if approved, the drug would be the first new drug to treat colorectal cancer in more than five years, according to a Los Angeles Times report.
The drug is indicated for use in patients who have failed with other treatment options, and a new clinical trial shows it can slow tumor growth and extend life. The most recent study was a phase-three study of 760 patients with advanced, metastasized colorectal cancer who underwent other failed treatment options. Patients given regorafenib survived for an average of 6.4 months, nearly a month and a half longer than patients given the placebo.
Related Articles on Gastroenterology:
Researchers Studying Link Between Gut Health and Other Diseases
Study: Bypass Better Than Gastric Banding for Weight Loss
Dr. Tim Rubin Featured on Medical Show for Fecal Transplant Procedure
The drug is indicated for use in patients who have failed with other treatment options, and a new clinical trial shows it can slow tumor growth and extend life. The most recent study was a phase-three study of 760 patients with advanced, metastasized colorectal cancer who underwent other failed treatment options. Patients given regorafenib survived for an average of 6.4 months, nearly a month and a half longer than patients given the placebo.
Related Articles on Gastroenterology:
Researchers Studying Link Between Gut Health and Other Diseases
Study: Bypass Better Than Gastric Banding for Weight Loss
Dr. Tim Rubin Featured on Medical Show for Fecal Transplant Procedure